Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

  title={Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity},
  author={G. Minotti and P. Menna and E. Salvatorelli and G. Cairo and L. Gianni},
  journal={Pharmacological Reviews},
  pages={185 - 229}
  • G. Minotti, P. Menna, +2 authors L. Gianni
  • Published 2004
  • Medicine
  • Pharmacological Reviews
  • The clinical use of anthracyclines like doxorubicin and daunorubicin can be viewed as a sort of double-edged sword. On the one hand, anthracyclines play an undisputed key role in the treatment of many neoplastic diseases; on the other hand, chronic administration of anthracyclines induces cardiomyopathy and congestive heart failure usually refractory to common medications. Second-generation analogs like epirubicin or idarubicin exhibit improvements in their therapeutic index, but the risk of… CONTINUE READING
    Role of anthracyclines in the era of targeted therapy
    • 185
    Editorial See P 555 Clinical Perspective on P 603
    • 2012


    Publications referenced by this paper.
    A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.
    • 1,837
    • Highly Influential
    A clinicopathologic analysis of adriamycin cardiotoxicity
    • 1,347
    • Highly Influential
    The anthracyclines: will we ever find a better doxorubicin?
    • 691
    Doxorubicin cardiotoxicity: analysis of prevailing hypotheses
    • 633
    Doxorubicin-induced cardiomyopathy.
    • 1,150
    Risk factors for doxorubicin-induced congestive heart failure.
    • 1,945
    • Highly Influential
    Cardiac dysfunction in the trastuzumab clinical trials experience.
    • 1,221
    • Highly Influential